Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 24, 2023
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

May 11, 2023
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

April 26, 2023
Chemomab Therapeutics to Present at Upcoming Scientific Conferences

April 19, 2023
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

April 12, 2023
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

March 29, 2023
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

March 17, 2023
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 06, 2023
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

February 21, 2023
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

January 03, 2023